<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04257851</url>
  </required_header>
  <id_info>
    <org_study_id>DTH:20001</org_study_id>
    <nct_id>NCT04257851</nct_id>
  </id_info>
  <brief_title>Is Theophylline More Effective Than Sumatriptan in the Treatment of Post-dural Puncture Headache</brief_title>
  <acronym>RCT</acronym>
  <official_title>Is Theophylline More Effective Than Sumatriptan in the Treatment of Post-dural Puncture Headache: A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Damanhour Teaching Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Damanhour Teaching Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives: To compare the safety and efficacy of oral theophylline versus oral sumatriptan
      in the treatment of post-dural puncture headache (PDPH).

      Background: PDPH is the most frequent complication of procedures associated with dural
      puncture for spinal anesthesia or following accidental dural puncture during epidural
      anesthesia. Since invasive treatments have known complications, pharmacologic management may
      be preferable.

      Patients and Methods: This was a prospective, randomized, double-blind, phase four clinical
      trial; carried out on 60 patients presented with PDPH at our hospital. Patients were randomly
      allocated into two equal groups (30 patients each); group T, received oral theophylline, and
      group S, received oral sumatriptan.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median and Range of Numeric Pain Rating Scale (NPRS) score</measure>
    <time_frame>48 hours after initiation of treatment</time_frame>
    <description>NPRS measures the severity of PDPH, it is a 11 point scale from 0-10; where 0=No pain and 10=Worst possible pain (before, 2h, 6h, 12h, then every 12h till 48h)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean and Standard deviation of PDPH duration (hours) (mean±SD)</measure>
    <time_frame>48 hours after initiation of treatment</time_frame>
    <description>Time from PDPH onset till NPRS score ≤ 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants and Rate of Treatment-related complications</measure>
    <time_frame>48 hours after initiation of treatment</time_frame>
    <description>Number of participants and Rate of: Palpitation, Tightness in the chest/throat/neck/jaws, Tingling sensation, Warm sensations in the body, Dizziness, Drowsiness, Nausea, Vomiting, Diarrhea.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Post-Dural Puncture Headache</condition>
  <arm_group>
    <arm_group_label>Group T (n=30)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Theophylline group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group S (n=30)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sumatriptan group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Theophylline Anhydrous Oral Tablet</intervention_name>
    <description>Theophylline tablet (150 mg/12h)</description>
    <arm_group_label>Group T (n=30)</arm_group_label>
    <other_name>Quibron-T/SR tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sumatriptan Succinate Oral Tablet</intervention_name>
    <description>Sumatriptan tablet (25 mg/12h)</description>
    <arm_group_label>Group S (n=30)</arm_group_label>
    <other_name>Imigran tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with NPRS score of ≥ 5

          -  American Society of Anesthesiologists (ASA) physical status ≤ II

          -  Age from 21 to 50 years

        Exclusion Criteria:

          -  Patients with NPRS score &lt; 5

          -  ASA physical status &gt; II

          -  Age &lt; 21 years or &gt; 50 years

          -  Pregnant women

          -  History of; Chronic headache, Cluster headache, Migraine

          -  History of; Convulsions, Cerebrovascular accident, Previous neurological diseases

          -  Signs of meningismus

          -  Arrhythmia

          -  Hypertension

          -  Ischemic heart disease

          -  Hyperthyroidism

          -  History of peripheral vascular disease (ischemic colitis)

          -  Use of selective serotonin reuptake inhibitors (SSRIs)

          -  Use of ergotamine derivatives in the past 24 hours

          -  Use of mono amino oxide inhibitors (MAOIs) in the last two weeks

          -  Use of any kind of opiates

          -  Liver or Renal impairment

          -  Allergy to the study medications

          -  Any contraindication of oral intake
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed M Shaat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Damanhour Teaching Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahmed M Shaat, MD</last_name>
    <phone>00201223482709</phone>
    <email>ahmedshaat99@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Damanhour Teaching Hospital</name>
      <address>
        <city>Damanhūr</city>
        <state>El-Beheira</state>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed M Shaat, MD</last_name>
      <phone>00201223482709</phone>
      <email>ahmedshaat99@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 4, 2020</study_first_submitted>
  <study_first_submitted_qc>February 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2020</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Post-dural puncture headache</keyword>
  <keyword>Spinal anesthesia</keyword>
  <keyword>Sumatriptan</keyword>
  <keyword>Theophylline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Post-Dural Puncture Headache</mesh_term>
    <mesh_term>Headache</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sumatriptan</mesh_term>
    <mesh_term>Theophylline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

